Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
14%
Ph phase_2
4
29%
Ph phase_3
8
57%

Phase Distribution

2

Early Stage

4

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
8(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(14)

Detailed Status

Completed14

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (14.3%)
Phase 24 (28.6%)
Phase 38 (57.1%)

Trials by Status

completed14100%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT00192231Phase 3

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

Completed
NCT00192348Phase 1

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

Completed
NCT00192192Phase 3

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

Completed
NCT00192270Phase 2

Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children

Completed
NCT00192309Phase 2

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

Completed
NCT00224783Phase 1

Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

Completed
NCT00192283Phase 3

Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers

Completed
NCT00192166Phase 2

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

Completed
NCT00111579Phase 2

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Completed
NCT00192335Phase 3

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Completed
NCT00192361Phase 3

Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)

Completed
NCT00192400Phase 3

Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.

Completed
NCT00217230Phase 3

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

Completed
NCT00192426Phase 3

Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14